Project
Checkmate 73L (CA20973L)
Automatically Closed ยท 2020 until 2023
Glatzer Markus
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2020
End Date
2023
Financing
EU
Brief description/objective
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent
Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT
Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally
Advanced Non-small Cell Lung Cancer (LA NSCLC)